BibTex RIS Cite

Assesment of the effect of alendronate therapy on urine calcium/creatinine ratio in patients with senil osteoporosis

Year 2011, Volume: 1 Issue: 1, 42 - 46, 31.01.2014

Elçin Yörükoğlu Betül Okuyan Mesut Sancar Fikret İzzettin

Abstract

Objective: In this study, it is aimed to assess the effects of alendronate treatment on urinary calcium/creatinine ratio in female patients newly diagnosed as senile osteoporosis and prescribed alendronate treatment.
Method: According to this aim, urinary calcium/creatinine ratio were measured at baseline and after 3 months alendronate therapy and also the levels of serum calcium , phosphorus, alkaline phosphatase (ALP), parathyroid hormone (PTH) were evaluated.
Results: Statistically significant decreases in serum ALP, calcium and phosphorus levels and urinary calcium/creatinine ratio were observed and as a response to these alterations, serum PTH levels were increased significantly after three months therapy (p<0.05).
Conclusion: It was found that urinary calcium/creatinine ratio can be used in evaluation of treatment efficacy and adherence of patients with osteoporosis at the beginning of the therapy.

Key words: Alendronate, osteoporosis, urinary calcium/creatinine ratio

Keywords

-

References

  • Yanık B, Atalar H, Külcü DG, Gökmen D. Postmenopozal Kadınlarda Vücut Kütle İndeksinin Kemik Mineral Yoğunluğuna Etkisi. Osteoporoz Dünyasından. 2007; 13: 56-59.
  • O’Connell MB, Vondracek SF. Osteoporosis and Other Metabolic Bone Diseases. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy APathophysiologic Approach. 7th ed. McGraw- Hill Companies; 2008, p.1483-1504.
  • Garnero P. Markers of Bone Turnover for Monitoring Antiresorptive Treatment of Osteoporosis. Journal für Menopause. 2000; 7 (Suppl 2): 49-51.
  • Küçük S, Gökdeniz R, Atmaca R, Uryan İ, Buhur A, Taşkın Ö. Effect of etidronate on urinary calcium/creatinin ratio in postmenopausal women: a prospective, randomized, placebo controlled study. Tr J of Medical Sciences. 1999; 29: 683-687.
  • Bartl R, Frisch B. Osteoporosis: Diagnosis, Prevention, Therapy. Çeviren (Ed): Tan AA Osteoporoz Teşhis, Korunma, Tedavi. Ankara: Orta Doğu Reklam Tanıtım ve Yayıncılık A.Ş. Türkiye Klinikleri Yayın; 2006, p.128-143.
  • Russell RG:. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006; 1068:367-401.
  • Bonnick S, Saag KG, Kiel PD. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006; 91: 2631-2637.
  • Swaminathan R. Biochemical markers of bone turnover. Clin Chim Acta. 2001; 313 (1-2): 95-105.
  • Eastell R., Hannon RA. Biochemical markers of bone turnover. In: Lobo RA, eds. Treatment of the Postmenopausal Women: Basic and Clinical Aspects. San Diego, California: Elsevier Academic Press; 2007, p.337- 349.
  • Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med. 2006; 119 (Suppl 1): 25-31.
  • Garnero P, Darte C, Delmas PD. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone. 1999; 24 (6): 603-609.
  • Chesnut CH 3rd, Harris ST. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. Osteoporos Int. 1993; 3 (Suppl 3): 17-19.
  • Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland- Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998; 13 (9): 1431-1438.
  • Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double- blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2005; 90 (5): 2762-2767.
  • Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Kaneda K, Minaguchi H, Inoue T, Tomita A, Nagata Y, Nakashima M, Orimo H. A placebo- controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. Endocr J. 1998: 45 (2): 191-201.
  • McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G el-H, Reda C, Yates AJ, Ravn P. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Ann Intern Med. 1998; 128 (4): 253-261.
  • Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem. 2001; 38 (6): 608-623.
  • Choi HJ, Im JA, Kim SH. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss. Maturitas. 2008; 60 (2): 170-176.
  • D’Amelio P, Grimaldi A, Cristofaro MA, Ravazzoli M, Molinatti PA, Pescarmona GP, Isaia GC. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int. 2010; 21(10): 1741-1750.
  • Smith ML, Fogelman I, Hart DM, Scott E, Bevan J, Leggate I. Effect of etidronate disodium on bone turnover following surgical menopause. Calcif Tissue Int. 1989; 44 (2): 74-79.
  • Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci. 2006; 1092: 385-396.
  • Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem. 1999; 45 (8):1353-1358.
  • Haspolat K, Boşnak M. Çocuklarda osteoporoz. Türkiye Klinikleri Fiziksel Tıp ve Rehabilitasyon Dergisi. 2002; 2 (1): 40-51.

Alendronat tedavisinin senil osteoporozlu hastalarda idrar kalsiyum/kreatinin oranı üzerine etkisinin değerlendirilmesi

Year 2011, Volume: 1 Issue: 1, 42 - 46, 31.01.2014

Elçin Yörükoğlu Betül Okuyan Mesut Sancar Fikret İzzettin

Abstract

Amaç: Bu çalışmada, alendronat kullanan senil osteoporozlu kadınlarda alendronat tedavisinin idrar kalsiyum/kreatinin oranları üzerine etkisinin değerlendirilmesi amaçlanmıştır.
Yöntem: Bu amaçla, tedavi öncesi ve 3 aylık tedavi sonrasında hastaların idrar kalsiyum/kreatinin oranları ölçülmüş ve ayrıca serum kalsiyum, fosfor, alkalen fosfataz (ALP), paratiroid hormon (PTH) değerlerinin sonuçları değerlendirilmiştir.
Bulgular: 3 aylık tedaviden sonra idrar kalsiyum/kreatinin oranında ve serum ALP, kalsiyum ve fosfor düzeylerinde istatistiksel olarak anlamlı bir düşüş ve serum PTH düzeyinde de bu değişikliklere cevap olarak anlamlı yükselme görülmüştür (p<0.05).
Sonuç: Tedavi başlangıcında osteoporoz hastalarının tedavi etkinliğinin ve uyuncunun değerlendirilmesi için idrar kalsiyum/kreatinin oranının izlem parametresi olarak kullanılabileceği sonucuna varılmıştır. 

Anahtar Kelimeler: Alendronat, osteoporoz, idrar kalsiyum/kreatinin oranı

Keywords

Alendronat osteoporoz idrar kalsiyum/kreatinin oranı

References

  • Yanık B, Atalar H, Külcü DG, Gökmen D. Postmenopozal Kadınlarda Vücut Kütle İndeksinin Kemik Mineral Yoğunluğuna Etkisi. Osteoporoz Dünyasından. 2007; 13: 56-59.
  • O’Connell MB, Vondracek SF. Osteoporosis and Other Metabolic Bone Diseases. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy APathophysiologic Approach. 7th ed. McGraw- Hill Companies; 2008, p.1483-1504.
  • Garnero P. Markers of Bone Turnover for Monitoring Antiresorptive Treatment of Osteoporosis. Journal für Menopause. 2000; 7 (Suppl 2): 49-51.
  • Küçük S, Gökdeniz R, Atmaca R, Uryan İ, Buhur A, Taşkın Ö. Effect of etidronate on urinary calcium/creatinin ratio in postmenopausal women: a prospective, randomized, placebo controlled study. Tr J of Medical Sciences. 1999; 29: 683-687.
  • Bartl R, Frisch B. Osteoporosis: Diagnosis, Prevention, Therapy. Çeviren (Ed): Tan AA Osteoporoz Teşhis, Korunma, Tedavi. Ankara: Orta Doğu Reklam Tanıtım ve Yayıncılık A.Ş. Türkiye Klinikleri Yayın; 2006, p.128-143.
  • Russell RG:. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006; 1068:367-401.
  • Bonnick S, Saag KG, Kiel PD. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006; 91: 2631-2637.
  • Swaminathan R. Biochemical markers of bone turnover. Clin Chim Acta. 2001; 313 (1-2): 95-105.
  • Eastell R., Hannon RA. Biochemical markers of bone turnover. In: Lobo RA, eds. Treatment of the Postmenopausal Women: Basic and Clinical Aspects. San Diego, California: Elsevier Academic Press; 2007, p.337- 349.
  • Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med. 2006; 119 (Suppl 1): 25-31.
  • Garnero P, Darte C, Delmas PD. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone. 1999; 24 (6): 603-609.
  • Chesnut CH 3rd, Harris ST. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. Osteoporos Int. 1993; 3 (Suppl 3): 17-19.
  • Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland- Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998; 13 (9): 1431-1438.
  • Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double- blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2005; 90 (5): 2762-2767.
  • Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Kaneda K, Minaguchi H, Inoue T, Tomita A, Nagata Y, Nakashima M, Orimo H. A placebo- controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. Endocr J. 1998: 45 (2): 191-201.
  • McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G el-H, Reda C, Yates AJ, Ravn P. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Ann Intern Med. 1998; 128 (4): 253-261.
  • Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem. 2001; 38 (6): 608-623.
  • Choi HJ, Im JA, Kim SH. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss. Maturitas. 2008; 60 (2): 170-176.
  • D’Amelio P, Grimaldi A, Cristofaro MA, Ravazzoli M, Molinatti PA, Pescarmona GP, Isaia GC. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int. 2010; 21(10): 1741-1750.
  • Smith ML, Fogelman I, Hart DM, Scott E, Bevan J, Leggate I. Effect of etidronate disodium on bone turnover following surgical menopause. Calcif Tissue Int. 1989; 44 (2): 74-79.
  • Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci. 2006; 1092: 385-396.
  • Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem. 1999; 45 (8):1353-1358.
  • Haspolat K, Boşnak M. Çocuklarda osteoporoz. Türkiye Klinikleri Fiziksel Tıp ve Rehabilitasyon Dergisi. 2002; 2 (1): 40-51.
There are 23 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Elçin Yörükoğlu This is me

Betül Okuyan

Mesut Sancar

Fikret İzzettin

Publication Date January 31, 2014
Submission Date November 1, 2013
Published in Issue Year 2011 Volume: 1 Issue: 1

Cite

APA Yörükoğlu, E., Okuyan, B., Sancar, M., İzzettin, F. (2014). Alendronat tedavisinin senil osteoporozlu hastalarda idrar kalsiyum/kreatinin oranı üzerine etkisinin değerlendirilmesi. Clinical and Experimental Health Sciences, 1(1), 42-46.
AMA Yörükoğlu E, Okuyan B, Sancar M, İzzettin F. Alendronat tedavisinin senil osteoporozlu hastalarda idrar kalsiyum/kreatinin oranı üzerine etkisinin değerlendirilmesi. Clinical and Experimental Health Sciences. January 2014;1(1):42-46.
Chicago Yörükoğlu, Elçin, Betül Okuyan, Mesut Sancar, and Fikret İzzettin. “Alendronat Tedavisinin Senil Osteoporozlu Hastalarda Idrar kalsiyum/Kreatinin Oranı üzerine Etkisinin değerlendirilmesi”. Clinical and Experimental Health Sciences 1, no. 1 (January 2014): 42-46.
EndNote Yörükoğlu E, Okuyan B, Sancar M, İzzettin F (January 1, 2014) Alendronat tedavisinin senil osteoporozlu hastalarda idrar kalsiyum/kreatinin oranı üzerine etkisinin değerlendirilmesi. Clinical and Experimental Health Sciences 1 1 42–46.
IEEE E. Yörükoğlu, B. Okuyan, M. Sancar, and F. İzzettin, “Alendronat tedavisinin senil osteoporozlu hastalarda idrar kalsiyum/kreatinin oranı üzerine etkisinin değerlendirilmesi”, Clinical and Experimental Health Sciences, vol. 1, no. 1, pp. 42–46, 2014.
ISNAD Yörükoğlu, Elçin et al. “Alendronat Tedavisinin Senil Osteoporozlu Hastalarda Idrar kalsiyum/Kreatinin Oranı üzerine Etkisinin değerlendirilmesi”. Clinical and Experimental Health Sciences 1/1 (January 2014), 42-46.
JAMA Yörükoğlu E, Okuyan B, Sancar M, İzzettin F. Alendronat tedavisinin senil osteoporozlu hastalarda idrar kalsiyum/kreatinin oranı üzerine etkisinin değerlendirilmesi. Clinical and Experimental Health Sciences. 2014;1:42–46.
MLA Yörükoğlu, Elçin et al. “Alendronat Tedavisinin Senil Osteoporozlu Hastalarda Idrar kalsiyum/Kreatinin Oranı üzerine Etkisinin değerlendirilmesi”. Clinical and Experimental Health Sciences, vol. 1, no. 1, 2014, pp. 42-46.
Vancouver Yörükoğlu E, Okuyan B, Sancar M, İzzettin F. Alendronat tedavisinin senil osteoporozlu hastalarda idrar kalsiyum/kreatinin oranı üzerine etkisinin değerlendirilmesi. Clinical and Experimental Health Sciences. 2014;1(1):42-6.

14639   14640